

MECHANISMS UNDERLYING REDUCTIONS IN MOTHER-TO-CHILD  
TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 BY SHORT-  
COURSE ANTIRETROVIRALS

Diana Bettina Schramm

A thesis submitted to the Faculty of Health Sciences, University of the Witwatersrand,  
Johannesburg, for the Degree of Doctor of Philosophy

Johannesburg, 2006

## ABSTRACT

Knowledge of the timing of mother-to-child transmission (MTCT) of HIV-1 is an important issue in reducing the risk of infant infection. Prior to giving birth therefore an HIV-1 positive mother should be provided with anti-HIV-1 drugs (antiretrovirals) during the shortest time possible to ensure both efficacy and minimal toxicity of the antiretrovirals to the newborn. However, in the absence of timely administration of nevirapine (NVP) or zidovudine (AZT) to the mother at the onset of labour, infants are given post-exposure prophylaxis (PEP). Despite antiviral prophylaxis some infants still become infected. In an attempt to mimic the *in vivo* scenario we investigated, in Chapter Three, the replication ability of a primary isolate (M502L) in peripheral blood mononuclear cells (PBMC) isolated from healthy donors exposed to different concentrations of NVP or AZT either prior to or post-infection, but that reflected mean neonatal plasma concentrations measured following maternal dosing. In phytohaemagglutinin (PHA) stimulated cultures M502L exhibited some growth. Maintaining NVP and AZT in the culture medium resulted in decreased viral growth over time. In contrast to that expected certain donors demonstrated elevated p24 antigen levels in the presence of HIV-1 and NVP or AZT. This suggested that cells were more conducive to HIV-1 replication either because of cellular activation or due to cellular production of cytokines/chemokines. The *in vitro* study highlighted (i) the differential permissiveness of cells from different donors for HIV-1 infection, (ii) different abilities of antiretrovirals (ART) to circumvent infection in different individuals and (iii) immunomodulatory effects of ART *in vitro*.

Commencing in Chapter Four we elected to investigate, *in vivo*, the immunomodulatory consequences of HIV-1 exposure and infection in two groups of HIV-1-exposed newborns whose mothers either received NVP at the onset of labour or who only received NVP as PEP within 72 hours of birth. Short-course antiretroviral drug regimens are known to reduce the risk of MTCT of HIV-1 but mechanisms affording protection of such interventions remain poorly defined. Since T-cell activation is an important factor in productive HIV-1 infection, we tested the hypothesis that single-dose NVP reduces immune activation, which in turn reduces the likelihood of transmission. We compared concentrations of cord and maternal blood plasma immune activation markers, neopterin,  $\beta_2$ -microglobulin ( $\beta_2$ -m) and soluble L-selectin (sL-selectin) in the two groups of HIV-1-

exposed newborns and among HIV-unexposed controls. *In utero* exposure of the infant to HIV-1, regardless of NVP exposure, led to demonstrable increases in levels of immune activation markers, this being most notable in the presence of pre-existing infection. Contrary to what was hypothesized, immune activation was increased by pre-birth exposure to single-dose NVP, with this effect being enhanced in infants already infected at birth. Our data suggest that reductions in immune activation do not explain transmission prevention effects of single-dose NVP. Our data also suggest a biological explanation for why HIV-1 infected infants exposed perinatally to antiretroviral drugs might experience hastened disease progression, namely that the immunological milieu in some HIV-1 infected individuals treated with NVP favours increased HIV-1 replication.

Cytokines and chemokines function to stimulate, or suppress cellular proliferation and differentiation and have unique immunomodulatory properties. Furthermore, they have the potential to protect against HIV-1 infection or to regulate HIV-1 replication. In Chapter Five we therefore questioned whether exposure to HIV-1 or NVP influences cytokine/chemokine levels of infants born to HIV-1 infected mothers. We compared levels of interleukin (IL)-7, IL-10, stromal cell-derived factor: SDF-1 $\alpha$  (CXCL12), granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage inflammatory protein-1 $\alpha$ : MIP-1 $\alpha$  (CCL3), macrophage inflammatory protein-1 $\beta$ : MIP-1 $\beta$  (CCL4) and regulated upon activation, normal T-cell expressed and secreted: RANTES (CCL5) of the two groups of HIV-1-exposed newborns and among the HIV-unexposed controls. HIV-1 exposure in the absence of single-dose NVP was not found to impact significantly on the levels of IL-7, IL-10, GM-CSF, CXCL12, CCL3, CCL4 or CCL5 and single-dose NVP had no appreciable effect on these cytokine/chemokine levels. Cord blood plasma levels of IL-7, CXCL12 and GM-CSF were found to be independent of mothers' levels. Single-dose NVP reduced the ability of cord blood mononuclear cell (CBMC) to produce GM-CSF spontaneously. Maternal and infant (HIV-1 exposed NVP unexposed) IL-10 levels were significantly correlated. Significantly elevated levels of IL-10 were associated with pre-existing infection in NVP unexposed newborns. CCL3, CCL4 and CCL5 levels in NVP unexposed uninfected infants were not different from those of control infants but correlated significantly with IL-7 levels.

HIV-1 specific cellular immune responses are elicited in a proportion of infants born to HIV-1 seropositive mothers and have been associated with protection from maternal

HIV-1 transmission. In Chapter Six, levels of the immune activation markers neopterin,  $\beta_2$ -m, sL-selectin, the immunomodulatory and haematopoietic factors IL-7, CXCL12, GM-CSF and the immunoregulatory cytokine IL-10 were examined amongst the group of newborns, that received NVP as PEP within 72 hours of birth, of which a proportion had specific cellular responses to HIV-1 envelope (Env) peptides. It was our aim to determine in infants that elicit HIV-1 specific cellular immune responses (Env<sup>+</sup>) and those that lack the specific responses (Env<sup>-</sup>), whether these factors could predict transmission and whether the former group of infants exhibit unique immune features that might distinguish them from Env<sup>-</sup> non-responders. Our data suggested that none of the factors tested were predictive of HIV-1 transmission but confirmed that infants with cellular responses to HIV-1 envelope peptides were associated with lack of subsequent infection. In particular, our data demonstrated an association between HIV-1 specific cellular immune responses, lower maternal viral load and lack of infection suggesting that sustained exposure to antigen (reduced maternal viral load) may be responsible for the strong priming effect. Furthermore, an association between reduced GM-CSF levels and the presence of HIV-1 specific responses was demonstrated, which suggested therefore that newborn infants that elicited HIV-1 specific cellular immune responses exhibited different immune capabilities from those without responses.

Finally, in Chapter Seven we looked at how immune activation and priming impact on thymic output of T-cells in newborn infants. Unfortunately, sample volumes of the two groups of HIV-1-exposed newborns used in the previous three Chapters became limited with the result that we chose to address these questions using anonymously collected cord blood samples from infants, some of which were used to supplement the placebo group of the the UNAIDS-sponsored clinical trial of short-course zidovudine-lamivudine (AZT-3TC). At the time the AZT-3TC trial was conducted short-course antiviral prophylaxis was not the standard of care for the prevention of MTCT of HIV-1. The thymus is known to be essential for establishing diversity of the T-cell pool, and morphological thymic changes and effects on naïve T-cells and T-cell receptor excision circle (TREC) concentrations have been reported in studies of HIV-1 infected children and adults. As it is not known to what extent *in utero* exposure to HIV-1 and infection affects T-cell division in newborn infants, we elected to determine TREC levels of infants born to HIV-1 seropositive mothers that were not exposed to antiretrovirals. The impact of increased immune activation on TREC levels and the consequence of HIV-1 exposure or infection

on circulating levels of IL-7 (raised levels indicative of T-cell depletion) was also investigated. HIV-1 exposure or infection did not result in significant losses of TREC. TREC levels were not affected by immune activation associated with HIV-1 exposure and infection and IL-7 levels were not raised. Infants that elicited HIV-1 specific cellular immune responses exhibit TREC levels that were similar to those of infants without HIV-1 specific responses. These data suggested that newborn infants of HIV-1 seropositive mothers demonstrated no altered thymopoietic ability compared to control infants. Furthermore, HIV-1 specific immune responses, (indicative of post-thymic memory T-cell expansion) did not influence thymic output measured in newborn infants.

In conclusion, the *in vitro* study demonstrated that there is a high degree of variability between PBMC isolated from different donors with respect to viral replication and drug effectivity which suggests that these phenomena are likely to exist within patient (infant as well as adult) populations. While immune activation is considered central to productive infection we demonstrated that immune activation is increased by HIV-1 exposure and by single-dose NVP. Exposure to HIV-1 alone or with NVP did not influence birth levels of IL-7, IL-10, CXCL12, GM-CSF, CCL3, CCL4 and CCL5. Furthermore, levels of these factors did not predict infection outcome in the infant. Immune activation and haematopoietic growth factors are modulated independently of the mother but maternal factors such as IL-10 and exposure to single-dose NVP, which reduces responsiveness of CBMC, could impact on the infant. HIV-1 specific cellular immune responses at birth, which are elicited in a proportion of infants born to HIV-1 positive mothers, are of immunological significance and can predict lack of subsequent infection. Disturbances in thymic output are not readily detectable at birth when using TREC to assess *de novo* T-cell synthesis, alternatively there is a homeostatic balance between thymic output and peripheral T-cell proliferation in newborns of HIV-1 infected mothers. Overall our data suggests that (i) there are immune consequences of being born to an HIV-1 positive mother, (ii) short-course antiretroviral prophylaxis does impact on the developing immune system of the infant and (iii) while the direct effects of single-dose NVP are not disputed, there are indirect consequences of NVP exposure on immune cells. Despite the consequences of HIV-1 exposure or the result of being born to a HIV-1 seropositive mother or exposure to single-dose NVP, our data proposes that the immune system of newborn infants is capable of responding as demonstrated by the enhanced immune activation. It remains important to determine the correlates of immune protection for the

development of novel immuno-therapeutic and vaccine strategies and maternal-infant transmission of HIV-1 provides a model which can address questions of protective immune processes. Understanding the influence of antiretrovirals on immune processes remains an important component of the drug mechanisms, (aside from their direct antiretroviral activity), that may underlie reductions in maternal-infant transmission of HIV-1. Furthermore, how antiretrovirals influence immune processes and immune development (together with exposure to HIV-1/consequences of being born to an HIV-1 seropositive mother), may impact on subsequent immune responsiveness to infectious organisms or childhood vaccines.

## DECLARATION

I declare that this thesis is my own, unaided work. It is being submitted for the degree of Doctor of Philosophy at the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at any other University.

---

Diana Schramm

\_\_\_\_\_ day of \_\_\_\_\_, 20\_\_

## **DEDICATION**

To those who have enriched and enlightened my life

Keep questioning and 'sapere aude'!

## ACKNOWLEDGEMENTS

With sincere thanks, I acknowledge :

My supervisor Prof Caroline Tiemessen for her valued input and comments and for giving me the opportunity to pursue this goal

Prof Louise Kuhn at the Gertrude H. Sergievsky Centre, College of Physicians and Surgeons and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York for her comments and advice

Prof Glenda Gray, and the team of nurses at the Perinatal HIV Research Unit at Chris Hani Baragwanath Hospital for the collection of mother and infant blood specimens and for the provision of the diagnostic and clinical data

Miss Dorinah Saleh for her help with the processing of specimens

Dr Tonie Cilliers for determining the co-receptor-utilising ability of the primary HIV-1 isolate used in this study

Dr Stephen Meddows-Taylor for determining T-helper cell responses

Prof Alan Landay and Prof Lena Al-Harthi at the Department of Immunology/Microbiology, Rush University, Rush-Presbyterian St. Luke's Medical Centre, Chicago, IL for allowing me to visit their laboratories and be trained in the technique of quantitating T-cell receptor excision circles

Mr John Voris for his help with training in the technique of quantitating T-cell receptor excision circles

The librarian at the National Institute for Communicable Diseases, Mrs Hazel Saevitzon

The Poliomyelitis Research Foundation of South Africa for their financial support

My parents, for their encouragement

To Rainer for his patience and ongoing motivation, support and encouragement

Last but definitely not least, to all the mother's who consented and were willing, with their infant's, to be part of these clinical trials. Without them most of this study would not have been possible

## PUBLICATIONS AND PRESENTATIONS

### Publications arising from PhD

Schramm DB, Kuhn L, Gray GE and Tiemessen CT (2006). *In vivo* effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1 seropositive mothers. *J Acquir Immune Defic Syndr* 42:545-553

Schramm DB, Meddows-Taylor S, Kuhn L, Gray GE and Tiemessen CT. Reduced GM-CSF levels are associated with HIV-1 specific cellular immune responses in HIV-1 exposed uninfected infants. (in preparation)

Schramm DB, Al-Harhi L., Landay A, Voris J, Kuhn L, Gray GE and Tiemessen CT. Thymic function is not altered in newborn infants of drug naïve HIV-1 infected mothers. (letter in preparation)

### Publications arising from other work carried out during PhD

Meddows-Taylor S, Donninger SL, Paximadis M, Schramm DB, Anthony FS, Gray GE, Kuhn L and Tiemessen CT (2006). Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmission. *J Gen Virol* 87:2055-2065

### Presentations

Molecular and Cell Biology Group Symposium

5 October 2006. University of the Witwatersrand, Gauteng

Oral presentation. CCL3L1 gene copy numbers in South African populations, and association with maternal-infant transmission of HIV-1

Donninger SL, Schramm DB, Paximadis M, Mathebula T, Puren A, Vardas E, Colvin M, Letsoalo M, Gray GE and Tiemessen CT

Health Sciences Research Day

23 August 2006. University of the Witwatersrand, Gauteng

Oral presentation. *In vivo* effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1 seropositive mothers.

Schramm DB, Kuhn L, Gray GE and Tiemessen CT

13<sup>th</sup> Conference on Retroviruses and Opportunistic Infections

Feb 5-9, 2006. Denver, Colorado, USA

Poster presentation. Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal HIV-1 transmission.

Tiemessen CT, Meddows-Taylor S, Donninger S, Paximadis M, Schramm DB, Anthony F, Gray GE and Kuhn L.

2<sup>nd</sup> South African AIDS Conference

June 7-10, 2005. Durban, South Africa

Oral presentation. Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal HIV-1 transmission.

Tiemessen CT, Meddows-Taylor S, Paximadis M, Donninger S, Kuhn L, Schramm DB, Anthony F and Gray GE.

2<sup>nd</sup> South African AIDS Conference

June 7-10, 2005. Durban, South Africa

Poster presentation. *In vivo* effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1 seropositive mothers.

Schramm DB, Kuhn L, Gray GE and Tiemessen CT.

2<sup>nd</sup> South African AIDS Conference

June 7-10, 2005. Durban, South Africa

Poster presentation. Reduced gene copy numbers of CCL3-L1 occur in HIV-1 infected South Africans? Implications for susceptibility to HIV/AIDS.

Donninger S, Schramm DB, Paximadis M, Mathebula T, Puren A, Vardas E, Colvin M, Letsoalo, Gray G and Tiemessen CT.

15<sup>th</sup> International AIDS Conference

July 11-16, 2004. Bangkok, Thailand

Poster presentation. Reduced ability of newborns to produce MIP-1 $\alpha$  and MIP-1 $\beta$  is associated with an increased susceptibility to perinatal HIV-1 transmission.

Meddows-Taylor S, Schramm DB, Gray GE, Kuhn L and Tiemessen CT.

Medical Virology Congress of South Africa

May 18-21, 2003. Berg-en-Dal, Kruger National Park, South Africa

Oral presentation. HIV-specific T-helper cell responses are suppressed among exposed-uninfected infants of mothers given single dose nevirapine prophylaxis.

Tiemessen CT, Meddows-Taylor S, Gray G, Schramm DB, Kuhn L.

10<sup>th</sup> Conference on Retroviruses and Opportunistic Infections.

February 10-14, 2003. Boston, MA.

Poster presentation. HIV-stimulated IL-2 production among exposed-uninfected infants of HIV-infected mothers given nevirapine prophylaxis.

Kuhn L, Meddows-Taylor S, Gray G, Schramm D, Tiemessen CT.

## CONTENTS

	<b>Page</b>
ABSTRACT.....	ii
DECLARATION.....	vii
DEDICATION.....	viii
ACKNOWLEDGEMENTS.....	ix
PUBLICATIONS AND PRESENTATIONS.....	xi
CONTENTS.....	xiv
LIST OF TABLES.....	xxii
LIST OF FIGURES.....	xxiv

### CHAPTER ONE

#### Literature review

1.1 HIV-1 prevalence and Africa.....	1
1.2 Maternal transmission of HIV-1.....	2
1.2.1 Factors influencing mode of perinatal transmission.....	2
1.2.2 Factors that correlate with the uninfected status of an infant.....	2
1.2.3 Molecular mechanisms and viral determinants involved in vertical transmission.....	4
1.2.4 Cellular mechanisms.....	5
1.2.5 Cell associated genital tract virus and vertical transmission of HIV-1.....	5
1.3 Dynamics at the maternal-foetal interface.....	5
1.3.1 The placenta and vertical transmission of HIV-1.....	6
1.3.2 Trophoblast involvement in <i>in utero</i> transmission of HIV-1.....	8
1.3.3 Transplacental passage of pathogens - mechanism of selective transmission of HIV-1 through the placental barrier.....	9
1.4 Antiretroviral prophylaxis of perinatal HIV-1 transmission in the developing world..	9
1.4.1 Infant HIV-1 prophylaxis.....	11
1.5 Developing world prophylaxis using zidovudine (AZT) or nevirapine (NVP) to reduce perinatal HIV-1 transmission.....	11
1.5.1 AZT prophylaxis.....	11
1.5.1.1 Pregnancy and AZT therapy on maternal viral load.....	12
1.5.2 NVP prophylaxis.....	12
1.6 Antiviral properties and characteristics of NVP and AZT.....	13
1.6.1 NRTIs.....	13

1.6.1.1 AZT.....	13
1.6.1.2 AZT transport and metabolism.....	13
1.6.1.3 Clinical pharmacokinetics of AZT.....	15
1.6.1.4 Safety and adverse effects of AZT.....	15
1.6.2 NNRTIs.....	16
1.6.2.1 NVP.....	16
1.6.2.2 NVP binding pocket.....	17
1.6.2.3 Clinical pharmacokinetics of NVP.....	18
1.6.2.4 NVP metabolism.....	19
1.6.2.5 Safety and adverse effects of NVP.....	19
1.7 Drug resistance.....	20
1.7.1 AZT drug resistance.....	21
1.7.2 NVP drug resistance.....	22
1.8 Pathogenesis of HIV-1 infection in infants and children.....	23
1.8.1 Molecular and biological properties of HIV-1 transmitted from mother-to-child.....	24
1.8.2 Cellular responses in perinatally HIV-1 infected or exposed uninfected infants.....	26
1.8.3 Cytokine profiles in vertically HIV-1 infected children.....	26
1.8.4 Host genetic factors and vertical transmission.....	27
1.8.5 Disease progression among infected infants despite antiretroviral prophylaxis..	28
1.9 Immunology of the newborn – immune competence in the neonate.....	30
1.9.1 Thymic development and early T-cell or thymocyte development.....	31
1.9.1.1 Generation of T-cell receptor diversity.....	32
1.9.1.2 Foetal thymic precursors.....	32
1.9.2 Immunophenotypic features of cord blood lymphocytes.....	33
1.9.2.1 Proliferative responses.....	34
1.9.2.2 Stimulation induced cytokine profile of cord blood.....	35
1.9.2.3 Cord blood lymphocyte chemokine receptor expression.....	37
1.9.3 Cord blood dendritic cells.....	37
1.9.4 Neonatal antigen-presenting cells.....	38
1.9.5 Mature antigen-specific T-cells.....	38
1.10 Interaction of HIV-1 with the immune system.....	38
1.10.1 HIV-1 in primary T-cells and the role of the cell cycle.....	39

1.10.2 HIV-1 infection of quiescent/nondividing cells.....	40
1.10.3 Latent infection of CD4 <sup>+</sup> T-cells.....	41
1.10.4 Integrated or unintegrated HIV-1 proviral DNA.....	41
1.11 Immune activation.....	42
1.11.1 Neopterin – a marker of cell-mediated immune responses.....	43
1.11.2 $\beta_2$ -microglobulin – a potential regulator of the immune system.....	44
1.11.3 L-selectin – involvement in specific immune responses.....	45
1.12 Factors involved in immunomodulation.....	46
1.12.1 IL-7.....	46
1.12.1.1 Role of IL-7 in HIV-1 infection.....	47
1.12.2 GM-CSF.....	48
1.12.2.1 Functional role of the GM-CSF receptor.....	48
1.12.2.2 Role of GM-CSF in HIV-1 infection.....	49
1.13 Cytokines and chemokines and their role in the immune system.....	50
1.13.1 Modulation of immune function by CXCL12.....	51
1.13.1.1 Role of CXCL12 and its receptor CXCR4 in HIV-1 infection.....	52
1.13.2 Modulation of immune function by CCL3, CCL4 and CCL5.....	53
1.13.2.1 Role of CCL3, CCL4, CCL5 and the receptors CCR5 and CXCR4 in HIV-1 infection.....	54
1.13.3 Modulation of immune function by IL-10.....	55
1.13.3.1 Role of IL-10 in HIV-1 infection.....	55
1.14 Effects of antiretroviral drugs on host cell function.....	56
1.15 Aims of the study.....	57
Specific objectives.....	58

## **CHAPTER TWO**

### **Materials and Methods**

2.1 <i>In vitro</i> studies.....	59
2.1.1 Isolation of PBMC from donor blood.....	59
2.1.1.1 Unstimulated and stimulated normal donor PBMC.....	60
2.1.2 Isolation of a primary HIV-1 isolate 98ZA502c3 (M502L).....	60
2.1.2.1 Virus stock titration.....	61
2.1.2.2 Viral infection.....	61
2.1.3 Antiretrovirals.....	62

2.1.3.1 Antiviral effect of NVP and AZT added pre-infection or post-infection to unstimulated and stimulated PBMC.....	62
2.1.4 Determination of p24 antigen production.....	63
2.2 <i>In vivo</i> studies.....	63
2.2.1 Study populations.....	63
2.2.1.1 Demonstration of antiretroviral therapy (DART) and post-exposure prophylaxis (PEP) cohorts.....	63
2.2.1.1.1 Infants demonstrating HIV-1 specific cellular immune responses.....	65
2.2.1.2 Anonomously collected cord blood samples.....	65
2.2.2 Blood samples.....	65
2.2.3 Cord blood mononuclear cell isolation.....	66
2.2.4 Determination of mothers' infection status.....	66
2.2.5 Qualitative virus determination.....	66
2.2.6 Quantitation of maternal and infant viral loads.....	67
2.2.7 Quantitation of mothers' CD4 T-cell counts.....	67
2.2.8 Enzyme linked immunosorbent assays.....	67
2.2.9 IL-2 production and ELISA assay.....	68
2.2.10 The <i>in vitro</i> ability of stimulated cord blood cells to produce haematopoietic growth factors.....	69
2.2.11 DNA preparation and quantitation.....	69
2.2.12 Real-time PCR for the quantitation of single joint T cell rearrangement excision circles (TREC).....	69
2.2.13 Statistical analysis.....	70

### **CHAPTER THREE**

#### **Varied replication ability of M502L, a primary HIV-1 isolate, in the presence of NVP and AZT in primary cultures**

3.1 Introduction.....	71
3.2 Results.....	74
3.2.1 Identifying the growth and inhibitory conditions for M502L which best mimic the <i>in vivo</i> setting where an HIV-1 seropositive mother at the onset of labour is given a single-dose NVP or the infant is given PEP.....	74
3.2.1.1 p24 Antigen production at different multiplicities of infection.....	74

3.2.1.2 Kinetics of M502L growth in PHA stimulated and unstimulated PBMC.....	74
3.2.1.3 Inhibition of HIV-1 infection by addition of NVP or AZT.....	76
3.2.1.4 Effect of drugs on cell viability in the absence of HIV-1 infection.....	80
3.2.2 <i>In vitro</i> studies to determine how timing of addition of NVP or AZT influences growth of M502L.....	81
3.2.2.1 Replication kinetics of M502L and drug inhibition of HIV-1 replication vary in PBMC isolated from different donors.....	81
3.2.2.1.1 Donor A.....	82
3.2.2.1.2 Donor B.....	83
3.2.2.1.3 Donor C.....	84
3.2.2.1.4 Donor D.....	86
3.2.2.1.5 Summary of M502L growth in different donors and inhibitory effects of NVP and AZT.....	88
3.2.3 <i>In vitro</i> studies to determine how timing of addition of NVP or AZT influences the ability to rescue M502L from unstimulated PBMC.....	89
3.2.3.1 Ability to rescue M502L following infection of ‘unstimulated’ PBMC with M502L.....	90
3.2.3.1.1 Donor E.....	91
3.2.3.1.2 Donor F.....	93
3.2.3.1.3 Donor G.....	95
3.2.3.1.4 Summary of viral growth in unstimulated cultures treated pre- or post-infection with NVP and AZT and the ability to rescue virus by PHA-stimulation at specific time points .....	97
3.3. Discussion.....	98

## **CHAPTER FOUR**

### **Cellular immune activation in the presence and absence of single-dose NVP**

4.1 Introduction.....	103
4.2 Results.....	105
4.2.1 Clinical characteristics of HIV-1 seropositive mothers and their infants.....	105
4.2.2 Infants exposed to or infected with HIV-1 demonstrate greater immune activation at birth than control uninfected infants.....	105

4.2.3 Single-dose NVP contributes to immune activation in infants born to HIV-1 seropositive mothers, particularly among infants infected <i>in utero</i> .....	106
4.2.4 Immune activation in the infant is modulated independently of the mother's viral load and is not influenced by gestation period.....	108
4.2.5 Single-dose NVP does not modulate immune activation markers of IP transmitting and non-transmitting HIV-1 infected mothers.....	108
4.2.6 Immune activation in the infant is modulated independently of that in the mother.....	110
4.3 Discussion.....	111

## **CHAPTER FIVE**

### **Consequences of HIV-1 exposure/infection and presence/absence of single-dose NVP exposure on cytokine and chemokine levels of newborn infants**

5.1 Introduction.....	116
5.2 Results.....	118
5.2.1 Clinical characteristics of HIV-1 seropositive mothers and their infants.....	118
5.2.2 NVP-unexposed infants exhibit similar levels of IL-7, IL-10, CXCL12, GM-CSF, CCL3, CCL4 and CCL5 to control infants.....	118
5.2.3 Single-dose NVP exposure has no appreciable effect on cytokine and chemokine levels in EU infants.....	118
5.2.4 Levels of factors do not differ significantly between exposed infants and those that become infected <i>in utero</i> or intrapartum in the presence or absence of single-dose NVP.....	118
5.2.5 Maternal status may influence immunomodulatory factors such as IL-10 in the infant.....	120
5.2.6 Haematopoietic growth factors are modulated independently of those in the mother.....	120
5.2.7 Correlations exist between haematopoietic growth factors in the newborn infant (control infants).....	120
5.2.7.1 Correlations exist between IL-7 and CXC- and CC-chemokines in exposed uninfected infants.....	121
5.2.8 CBMC of NVP-unexposed and NVP-exposed produce similar levels of IL-7, CXCL12 and GM-CSF when primed with HIV-1 Env peptides and PHA.....	121

5.3 Discussion.....	126
---------------------	-----

**CHAPTER SIX**

**Immune factor(s) of infants born to HIV-1 seropositive mothers that develop HIV-1 envelope specific cellular immune responses and those that do not**

6.1 Introduction.....	129
6.2 Results.....	131
6.2.1 Clinical characteristics of HIV-1 seropositive mothers and their infants.....	131
6.2.2 Levels of immune activation markers, immunomodulatory/immunoregulatory and haematopoietic cytokines do not predict maternal-infant HIV-1 transmission.....	131
6.2.3 Presence of T-helper envelope responses predict the lack of intrapartum transmission.....	131
6.2.4 Mothers of infants with HIV-1 specific cellular immune responses have lower viral loads.....	132
6.2.5 Infants with HIV-1 specific cellular immune responses exhibit different immune capabilities compared to those without responses.....	133
6.2.6 Infants with HIV-1 specific responses have reduced plasma GM-CSF levels...	136
6.2.7 CBMC of Env <sup>+</sup> infants exposed to HIV-1 demonstrated a reduced ability to produce GM-CSF in response to stimulation with PHA.....	136
6.2.8 Exposed-uninfected infants without HIV-1 cellular responses have significantly elevated plasma IL-10 levels.....	139
6.3 Discussion.....	140

**CHAPTER SEVEN**

**Thymic function in newborn infants of drug-naïve HIV-1 infected mothers**

7.1 Introduction.....	146
7.2 Results.....	148
7.2.1 Characteristics of infants.....	148
7.2.2 Infants exposed to HIV-1 demonstrate significant immune activation but not significant reductions in TREC concentrations.....	148
7.2.3 Cord blood plasma IL-7 levels do not reflect diminished thymic output.....	151
7.2.4 The presence of HIV-1 specific immune responses in cord blood do not influence thymic output measured in infants.....	151

7.3 Discussion.....	152
 <b>CHAPTER EIGHT</b>	
<b>Concluding remarks.....</b>	<b>157</b>
 <b>REFERENCES.....</b>	
<b>APPENDIX A: List of abbreviations.....</b>	<b>217</b>
<b>APPENDIX B: Antiretroviral agents in clinical use and under clinical development for adults and children.....</b>	<b>222</b>
<b>Table 1</b> Antiretroviral agents available to adults – their properties and clinical status.....	222
<b>Table 2</b> Antiretroviral agents under clinical development.....	223
<b>Table 3</b> Antiretroviral agents recommended in children under 3 months of age (Cohen <i>et al.</i> , 2002).....	224
<b>APPENDIX C: Clinical trials undertaken to investigate the efficacy of different antiretroviral regimens in reducing perinatal HIV-1 transmission...225</b>	
<b>Table 1</b> Phase 3 antiretroviral prophylaxis clinical trial regimens and their efficacy in reducing perinatal HIV-1 transmission.....	225
<b>APPENDIX D: Synthetic HIV-1 envelope peptides used to induce T-helper cell responses.....</b>	<b>226</b>
<b>Table 1</b> HIV-1 subtype B envelope peptides (Berzofsky <i>et al.</i> , 1991; Hale <i>et al.</i> , 1989; Cease <i>et al.</i> , 1987) used to stimulate IL-2 production.....	226
<b>APPENDIX E: Composition of buffers and media.....</b>	<b>227</b>
<b>APPENDIX F: List of suppliers.....</b>	<b>228</b>
<b>APPENDIX G: Statistical methods.....</b>	<b>231</b>
<b>APPENDIX H: Ethical clearance.....</b>	<b>233</b>

## LIST OF TABLES

<b>Table number and title</b>	<b>Page</b>
1.1 Factors associated with the risk of perinatal HIV-1 transmission.....	3
1.2 Natural history of HIV-1 infection in children.....	24
1.3 Ontogeny of foetal and neonatal immunity.....	30
1.4 Ability of cord blood T-lymphocytes to produce cytokines/chemokines using different stimuli for activation.....	36
2.1 HIV-1 seropositive mothers and their infants enrolled in the PEP and DART study trials showing numbers of infants selected for the nested case-control study.....	64
3.1 Percentage inhibition (relative to HIV-1 controls) of M502L replication in PHA-stimulated and unstimulated PBMC following addition of 10 µM NVP or 20 µM AZT either pre- or post-infection.....	78
3.2 Percentage inhibition (relative to HIV-1 controls) of M502L replication in PHA-stimulated and unstimulated PBMC following addition of 10 µM NVP or 20 µM AZT either pre- or post-infection.....	79
3.3 Percentage inhibition (relative to controls) of M502L (moi 0.01 and 0.005) in PHA stimulated PBMC isolated from a donor A and treated with either NVP (10 µM) or AZT (20 µM).....	83
3.4 Percentage inhibition (relative to HIV-1 controls) of M502L replication in PHA-stimulated PBMC from donor B following addition of 10 µM NVP or 20 µM AZT either pre- or post-infection.....	84
3.5 Percentage inhibition (relative to HIV-1 controls) of M502L replication in PHA-stimulated PBMC from donor C following addition of 10 µM NVP or 20 µM AZT either pre- or post-infection.....	86
3.6 Percentage inhibition (relative to HIV-1 controls) of M502L replication in PHA-stimulated PBMC from donor D following addition of 10 µM NVP or 20 µM AZT at different time periods either pre- or post-infection.....	87
3.7 Summary of M502L growth and ability of NVP (10µM) and AZT (20µM) to inhibit HIV-1 replication in different donors. Only significant data presented.....	88

3.8	Percentage inhibition (relative to HIV-1 controls) of M502L replication in unstimulated PBMC (donor E) following addition of 10 $\mu$ M NVP or 20 $\mu$ M AZT either pre- or post-infection.....	91
3.9	Percentage inhibition (relative to HIV-1 controls) of M502L replication in unstimulated PBMC (donor F) following addition of 10 $\mu$ M NVP or 20 $\mu$ M AZT either pre- or post-infection.....	93
3.10	Percentage inhibition (relative to HIV-1 controls) of M502L replication in unstimulated PBMC (donor G) following addition of 10 $\mu$ M NVP or 20 $\mu$ M AZT either pre- or post-infection.....	95
3.11	Summary of M502L viral growth in unstimulated donor PBMC following pre- or post-infection addition of NVP or AZT, and time points of PHA-stimulation that resulted in successful viral replication. Only statistically significant data are presented.....	97
4.1	Clinical characteristics of the HIV-seropositive mothers and their infants.....	105
4.2	Immune activation factor levels in plasma of mother and infant pairs.....	110
5.1	Median and interquartile ranges of levels of IL-7, IL-10, CXCL12, GM-CSF, CCL3, CCL4 and CCL5 of infants stratified based on infection outcome.....	119
5.2	IL-7, IL-10, CXCL12 and GM-CSF levels of mother and infantpairs.....	123
6.1	Maternal viral loads, maternal CD4 <sup>+</sup> T-lymphocyte counts and infant levels of immune factors.....	132
6.2	IL-2 dependent cellular immune responses of exposed uninfected and intrapartum infected infants as well as levels of the immunomodulatory and immunoregulatory cytokines of infants. Maternal viral load and CD4 <sup>+</sup> T-lymphocyte count's are also presented .....	134
7.1	Viral load, TREC determinations and immunological characteristics of infants.....	149
8.1	Infant plasma levels of immune factors associated with HIV-1 exposure/infection in the presence and absence of single-dose NVP and their association with IP transmission. Infant plasma levels relative to those of their mothers are also presented.....	160

## LIST OF FIGURES

Figure number and title	Page
1.1 Anatomy of the maternal- foetal interface, where the foetal-derived placenta attaches to the mother’s uterus.....	7
3.1 Growth of M502L in PHA-stimulated PBMC from a healthy donor.....	75
3.2 Growth kinetics of M502L (~2000 TCID <sub>50</sub> ) following infection of PHA stimulated and unstimulated PBMC for 1.5 hours or 24 hours .....	76
3.3 Inhibitory effect of increasing concentrations of NVP and AZT on M502L determined after 7 days of culture.....	77
3.4 The ability of 10 µM NVP or 20 µM AZT to inhibit the replication of M502L in PHA-stimulated PBMC when added either pre- or post-infection.....	78
3.5 The ability of NVP or AZT to inhibit the replication of M502L in freshly isolated PBMC (no PHA-stimulation), when added either pre- or post-infection.....	79
3.6 Effect of increasing concentrations of NVP and AZT on the viability of PHA-stimulated PBMC.....	80
3.7 Schematic diagram depicting the <i>in vivo</i> timing of ART administration to either the mother or to the infant and our <i>in vitro</i> experimental approach to mimic the <i>in vivo</i> setting.....	81
3.8 Replication kinetics of M502L in PHA-stimulated PBMC from donor A.....	82
3.9 Replication of M502L in PHA-stimulated PBMC from donor B.....	84
3.10 Growth of M502L in PHA stimulated PBMC from donor C infected at a moi of 0.01 and 0.005.....	85
3.11 Growth of M502L in PHA-stimulated PBMC from donor D infected at a moi of 0.01, with 10 µM NVP added at different time periods pre- or post-infection....	87
3.12 Schematic diagram depicting how timing of PHA-stimulation may influence viral infection outcome in unstimulated cultures treated pre- or post-infection with NVP or AZT.....	90
3.13 The inhibitory effect of NVP or AZT, added at different times to unstimulated PBMC cultures (donor E), either pre- or post-infection and the ability to rescue virus from this donor.....	92

3.14	The inhibitory effect of NVP or AZT, added at different times to unstimulated PBMC cultures (donor F), either pre- or post-infection and the ability to rescue virus from this donor.....	94
3.14	The inhibitory effect of NVP or AZT, added at different times to unstimulated PBMC cultures (donor G), either pre- or post-infection and the ability to rescue virus from this donor.....	96
4.1	Levels of soluble immune activation markers in plasma of infants born to HIV-1 seronegative and HIV-1 seropositive mothers.....	107
4.2	Levels of soluble immune activation markers of HIV-1 infected mothers grouped according to infection status of the infant and NVP exposure.....	109
5.1A	Ability of CBMC isolated from infants given PEP within 72 hours of birth to produce IL-7 (pg/ml), CXCL12 (pg/ml) and GM-CSF (pg/ml) spontaneously, in response to HIV-1 envelope peptides and PHA.....	124
5.1B	Ability of CBMC isolated from infants exposed to a single-dose of NVP to produce IL-7 (pg/ml), CXCL12 (pg/ml) and GM-CSF (pg/ml) spontaneously, in response to HIV-1 envelope peptides and PHA.....	125
6.1	Levels of neopterin (ng/ml), $\beta_2$ -m ( $\mu$ g/ml) and sL-selectin (ng/ml), of infants born to HIV-1 seropositive mothers in the absence of single-dose NVP (PEP) and stratified on the basis of infection outcome and cellular immune responses to HIV-1 envelope peptides (Env <sup>-</sup> and Env <sup>+</sup> ).....	135
6.2	Infant and maternal plasma GM-CSF levels.....	137
6.3	Ability of CBMC to produce GM-CSF (pg/ml) spontaneously, in response to HIV-1 envelope peptides and PHA.....	138
6.4	Levels of IL-10 (pg/ml) of infants born to HIV-1 seropositive mothers in the absence of single-dose NVP (PEP) and stratified on the basis of infection outcome and cellular immune responses to HIV-1 envelope peptides (Env <sup>-</sup> and Env <sup>+</sup> ).....	139
7.1	Cord blood plasma levels of neopterin and IL-7 and thymic function measured by analysis of TREC (Log <sub>10</sub> TREC copies/ $\mu$ g DNA) for uninfected (control) infants and infants born to HIV-1 infected mothers stratified on the basis of their viral loads.....	150
8.1	Possible outcomes of <i>in utero</i> viral exposure in infants born to HIV-1 seropositive mothers.....	163